In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.
Previous pharmacodynamic studies using in vivo candidiasis models have demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC is a good descriptor of the echinocandin exposure-response relationship. Further studies investigating the 24-h AUC/MIC target for a stasis endpoint identified free-drug 24-h AUC/MIC against Candida albicans and were similar for two echinocandins, anidulafungin and micafungin. The current studies expand investigation of a third echinocandin (caspofungin) and compare the pharmacodynamic target among C. albicans, Candida glabrata, and Candida parapsilosis. Treatment studies were conducted with six C. albicans, nine C. glabrata, and 15 C. parapsilosis strains with various MICs (anidulafungin, 0.015 to 4.0 microg/ml; caspofungin, 0.03 to 4.0 microg/ml; and micafungin, 0.008 to 1.0 microg/ml). Efficacy was closely tied to MIC and the 24-h AUC/MIC. Therapy against C. parapsilosis required more of each echinocandin on a mg/kg basis. Caspofungin required less drug on a mg/kg basis for efficacy against all of the organisms than did the other two drugs. However, the 24-h AUC/MIC targets were similar among the echinocandins when free drug concentrations were considered, suggesting the relevance of protein binding. The targets for C. parapsilosis (mean, 7) and C. glabrata (mean, 7) were significantly lower than those for C. albicans (mean, 20) for each echinocandin. The results suggest that current susceptibility breakpoints and the consideration of organism species in these determinations should be reexplored.
Andes
D
D
Department of Medicine and Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, WI 53792, USA. dra@medicine.wisc.edu
Diekema
D J
DJ
Pfaller
M A
MA
Bohrmuller
J
J
Marchillo
K
K
Lepak
A
A
D000077612:Anidulafungin; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects*; D002176:Candida albicans / Q000187:drug effects; D041221:Candida glabrata / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D000077336:Caspofungin; D054714:Echinocandins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D005260:Female; D007668:Kidney / Q000382:microbiology; D055666:Lipopeptides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D000077551:Micafungin; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D011485:Protein Binding; D013045:Species Specificity
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077612:Anidulafungin; D000077336:Caspofungin; D000077551:Micafungin
Pharmacotherapy. 2006 Jun;26(6):877-80
16716141
Clin Infect Dis. 2009 Mar 1;48(5):503-35
19191635
Antimicrob Agents Chemother. 2007 Nov;51(11):4214-6
17785512
Infection. 2002 Oct;30(5):286-91
12382088
Antimicrob Agents Chemother. 2003 Dec;47(12):3935-41
14638504
Mycoses. 2009 Nov;52(6):493-8
19207835
Antimicrob Agents Chemother. 2003 Apr;47(4):1187-92
12654645
Antimicrob Agents Chemother. 2006 Jul;50(7):2522-4
16801435
J Clin Microbiol. 2008 Aug;46(8):2659-64
18562582
N Engl J Med. 2007 Jun 14;356(24):2472-82
17568028
Antimicrob Agents Chemother. 2003 Oct;47(10):3165-9
14506026
Antimicrob Agents Chemother. 2002 Jun;46(6):1665-70
12019073
J Clin Microbiol. 2005 Nov;43(11):5425-7
16272464
Antimicrob Agents Chemother. 2008 Feb;52(2):539-50
18070979
J Antimicrob Chemother. 2006 Apr;57(4):705-8
16464893
Antimicrob Agents Chemother. 2007 Jun;51(6):2253-6
17420211
Lancet. 2007 May 5;369(9572):1519-1527
17482982
J Clin Microbiol. 2006 Mar;44(3):819-26
16517860
Antimicrob Agents Chemother. 2007 Mar;51(3):968-74
17194830
N Engl J Med. 2002 Dec 19;347(25):2020-9
12490683
J Clin Microbiol. 2008 Mar;46(3):842-9
18199791
Clin Infect Dis. 2006 Apr 1;42(7):938-44
16511756
Antimicrob Agents Chemother. 2006 Sep;50(9):3160-1
16940118
J Clin Microbiol. 2006 Mar;44(3):760-3
16517851
Curr Opin Infect Dis. 2001 Apr;14(2):165-72
11979128
Clin Infect Dis. 2007 Jan 1;44(1):79-86
17143821
Haematologica. 2008 Apr;93(4):639-40
18379015
Antimicrob Agents Chemother. 2004 Apr;48(4):1382-3
15047549
Antimicrob Agents Chemother. 2005 Dec;49(12):5058-68
16304173
Antimicrob Agents Chemother. 2003 Oct;47(10):3149-54
14506023
Diagn Microbiol Infect Dis. 2008 Mar;60(3):329-31
18024052
Clin Infect Dis. 1997 Feb;24(2):235-47
9114154
Antimicrob Agents Chemother. 2006 Nov;50(11):3695-700
16954319
Clin Infect Dis. 2006 Jul 15;43(2):215-22
16779750
J Clin Microbiol. 2006 Oct;44(10):3533-8
17021079
J Clin Pharmacol. 2005 Oct;45(10):1145-52
16172179
J Clin Microbiol. 2008 Jan;46(1):150-6
18032613
Clin Infect Dis. 2006 Apr 15;42(8):1171-8
16575738
Antimicrob Agents Chemother. 2005 Aug;49(8):3264-73
16048935
Antimicrob Agents Chemother. 2003 Apr;47(4):1179-86
12654644
Antimicrob Agents Chemother. 1997 Nov;41(11):2339-44
9371330
Antimicrob Agents Chemother. 2004 Jan;48(1):137-42
14693531
Clin Infect Dis. 2007 Oct 1;45(7):883-93
17806055
Antimicrob Agents Chemother. 2005 Sep;49(9):3616-23
16127030
J Infect Dis. 2004 Oct 15;190(8):1464-71
15378439
Antimicrob Agents Chemother. 2008 Oct;52(10):3497-503
18625768
J Infect. 2008 Feb;56(2):126-9
18082269
Antimicrob Agents Chemother. 2003 Apr;47(4):1193-9
12654646
Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2
9455502
Clin Infect Dis. 2003 Sep 1;37(5):634-43
12942393
Antimicrob Agents Chemother. 2008 Nov;52(11):4181-3
18794386
Methods Mol Med. 2005;118:111-28
15888938
Antimicrob Agents Chemother. 2009 Jan;53(1):112-22
18955538
Int J Antimicrob Agents. 2002 Apr;19(4):261-8
11978497
J Clin Microbiol. 2008 Aug;46(8):2620-9
18579718